A retrospective study of Volanesorsen in patients suffering from familial chylomicronemia syndrome (FCS), both before and during treatment periods
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2018
Price : $35 *
At a glance
- Drugs Volanesorsen (Primary)
- Indications Hyperlipoproteinaemia type I
- Focus Adverse reactions
- Acronyms ReFOCUS study
- 13 Jun 2018 According to an Akcea Therapeutics media release, results from this trial were published in the journal Expert Review of Cardiovascular Therapy.
- 03 May 2018 New trial record
- 26 Apr 2018 According to a Akcea Therapeutics media release, results from this study will be presented at the National Lipid Association (NLA) Scientific Sessions on Apr 2018 and at the European Atherosclerosis Society (EAS) 2018.